Experience

DualityBio Announces HK$1.64 Billion IPO

April 24, 2025

Cooley advised the underwriters of Duality Biologics (DualityBio), a clinical-stage biotech company focused on the discovery and development of next-generation antibody-drug conjugate therapeutics for patients with cancer and autoimmune diseases, in connection with its HK$1.64 billion global initial public offering (IPO).

Read more

Related contacts

Yiming Liu
Partner in Charge – Shanghai, Shanghai
Michael Yu
Partner in Charge – Hong Kong, Hong Kong
Xander Lee
Partner, Santa Monica
Vince Sampson
Special Counsel, Washington, DC
Karen Tsai
Special Counsel, Washington, DC
Monica Xu
Special Counsel, Shanghai
Hilda Li
Associate, Hong Kong
Zixiang Liu
Associate, Shanghai
Patrick Sharma
Associate, Santa Monica
Yiying Wang
Associate, Shanghai
Yunxiang Xu
Associate, Shanghai
Kaiting Yang
Associate, Hong Kong
Tonny Yu
Associate, Hong Kong
Tonny Yu
Associate, Hong Kong
Letian Wei
Legal Consultant, Shanghai
Cindy Pan
International Legal Project Manager, Hong Kong
Zoe Wang
International Legal Project Manager, Shanghai
Philip Kwan
Senior Legal Assistant, Hong Kong
Jin Wang
Senior Legal Assistant, Beijing

Related Practices & Industries

Harbour BioMed Announces $105.3 Million Share Subscription Agreement With AstraZeneca

March 21, 2025

Cooley advised Harbour BioMed (HBM Holdings, HKEX: 02142), a global biopharmaceutical company committed to the discovery, development and commercialization of novel antibody therapeutics in oncology and immunology, on its share subscription agreement with AstraZeneca.

Read more

Related contacts

Michael Yu
Partner in Charge – Hong Kong, Hong Kong
Kaiting Yang
Associate, Hong Kong
Ying Liu
Associate, Hong Kong
Cindy Pan
International Legal Project Manager, Hong Kong

Related Practices & Industries

D3 Bio Completes $62 Million Series A+

April 15, 2024

Cooley advised D3 Bio – an emerging global biotechnology company that focuses on discovery, development and registration of innovative cancer drugs – on the close of its $62 million Series A+ financing.

Read more

Related contacts

Andrew Harline
Partner in Charge – Singapore, Singapore
Lunga Su
Associate, Shanghai
Xander Lee
Partner, Santa Monica
Yiming Liu
Partner in Charge – Shanghai, Shanghai
Zack Gong
Associate, Shanghai
Qi Wang
Associate, Beijing
Kaiting Yang
Associate, Hong Kong
Cindy Pan
International Legal Project Manager, Hong Kong

Related Practices & Industries

ImmuneOnco Biopharmaceuticals – HK$319 Million IPO

September 5, 2023

Cooley advised ImmuneOnco Biopharmaceuticals, a clinical-stage biotechnology company dedicated to the development of immuno-oncology therapies, on its HK$319 million initial public offering.

Read more

Related contacts

Yiming Liu
Partner in Charge – Shanghai, Shanghai
Michael Yu
Partner in Charge – Hong Kong, Hong Kong
Xander Lee
Partner, Santa Monica
Francis Wheeler
Senior Counsel, Colorado
Eric Blanchard
Partner, Boston
Yiying Wang
Associate, Shanghai
Kaiting Yang
Associate, Hong Kong
Yunxiang Xu
Associate, Shanghai
Cecilia Bai
Associate , Singapore
Rick Jantz
Associate, Santa Monica
Cindy Pan
International Legal Project Manager, Hong Kong
Alex Wu
Associate, Shanghai
Zhengyang Li
International Legal Project Manager, Hong Kong

Related Practices & Industries

Laekna Announces Largest 18A IPO Year to Date at HK$791 Million

June 29, 2023

Cooley advised China International Capital Corporation Hong Kong Securities Limited (CICC) and other underwriters on Laekna’s HK$791 million (US$101 million) initial public offering of 63,728,000 shares on the Hong Kong Stock Exchange, the largest 18A offering year to date.

Read more

Related contacts

Michael Yu
Partner in Charge – Hong Kong, Hong Kong
Yiming Liu
Partner in Charge – Shanghai, Shanghai
Tonny Yu
Associate, Hong Kong
April Wang
Associate, Hong Kong
Cindy Pan
International Legal Project Manager, Hong Kong
Blake Cao
Senior Legal Assistant, Beijing
Philip Kwan
Senior Legal Assistant, Hong Kong
Zhengyang Li
International Legal Project Manager, Hong Kong

Related Practices & Industries